Dermapharm Holding SE
Dermapharm Holding SE Fundamental Analysis
Dermapharm Holding SE (DMPHF) shows strong financial fundamentals with a PE ratio of 13.62, profit margin of 11.37%, and ROE of 20.45%. The company generates $1.2B in annual revenue with moderate year-over-year growth of 4.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 52.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze DMPHF's fundamental strength across five key dimensions:
Efficiency Score
WeakDMPHF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentDMPHF trades at attractive valuation levels.
Growth Score
ModerateDMPHF shows steady but slowing expansion.
Financial Health Score
ModerateDMPHF shows balanced financial health with some risks.
Profitability Score
ModerateDMPHF maintains healthy but balanced margins.
Key Financial Metrics
Is DMPHF Expensive or Cheap?
P/E Ratio
DMPHF trades at 13.62 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, DMPHF's PEG of 1.16 indicates fair valuation.
Price to Book
The market values Dermapharm Holding SE at 2.60 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 2.95 times EBITDA. This is generally considered low.
How Well Does DMPHF Make Money?
Net Profit Margin
For every $100 in sales, Dermapharm Holding SE keeps $11.37 as profit after all expenses.
Operating Margin
Core operations generate 19.13 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $20.45 in profit for every $100 of shareholder equity.
ROA
Dermapharm Holding SE generates $6.01 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Dermapharm Holding SE produces operating cash flow of $227.15M, showing steady but balanced cash generation.
Free Cash Flow
Dermapharm Holding SE generates strong free cash flow of $185.03M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $3.44 in free cash annually.
FCF Yield
DMPHF converts 10.26% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
13.62
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.16
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.60
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.55
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.52
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.05
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.20
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How DMPHF Stacks Against Its Sector Peers
| Metric | DMPHF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 13.62 | 29.02 | Better (Cheaper) |
| ROE | 20.45% | 745.00% | Weak |
| Net Margin | 11.37% | -46183.00% (disorted) | Strong |
| Debt/Equity | 1.52 | 0.35 | Weak (High Leverage) |
| Current Ratio | 2.05 | 4.52 | Strong Liquidity |
| ROA | 6.01% | -17797.00% (disorted) | Weak |
DMPHF outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Dermapharm Holding SE's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
68.47%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
47.40%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
100.15%
Industry Style: Defensive, Growth, Innovation
High Growth